Sun Y - Search Results

1

Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression.

Wu G, Sun Y, Xiang Z, Wang K, Liu B, Xiao G, Niu Y, Wu D, Chang C. Wu G, et al. Among authors: sun y. Cell Death Dis. 2019 Jan 15;10(2):37. doi: 10.1038/s41419-018-1048-1. Cell Death Dis. 2019. PMID: 30674872 Free PMC article.

2

TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression.

Zhu J, Yang DR, Sun Y, Qiu X, Chang HC, Li G, Shan Y, Chang C. Zhu J, et al. Among authors: sun y. Mol Cancer Ther. 2015 Jun;14(6):1445-53. doi: 10.1158/1535-7163.MCT-14-0971. Epub 2015 Apr 1. Mol Cancer Ther. 2015. PMID: 25833838 Free PMC article.

3

TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals.

Qiu X, Zhu J, Sun Y, Fan K, Yang DR, Li G, Yang G, Chang C. Qiu X, et al. Among authors: sun y. Oncotarget. 2015 Jun 20;6(17):15397-409. doi: 10.18632/oncotarget.3778. Oncotarget. 2015. PMID: 25980442 Free PMC article.

4

Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.

Chen Y, Sun Y, Rao Q, Xu H, Li L, Chang C. Chen Y, et al. Among authors: sun y. Oncotarget. 2015 Oct 13;6(31):31203-15. doi: 10.18632/oncotarget.4522. Oncotarget. 2015. PMID: 26304926 Free PMC article.

5

Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.

Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X, Chang C. Shi L, et al. Among authors: sun y. Cancer Lett. 2016 Apr 1;373(1):45-56. doi: 10.1016/j.canlet.2016.01.017. Epub 2016 Jan 19. Cancer Lett. 2016. PMID: 26805759 Free PMC article.

6

Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.

Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C. Shi L, et al. Among authors: sun y. Mol Cancer Ther. 2016 Apr;15(4):731-742. doi: 10.1158/1535-7163.MCT-15-0706. Epub 2016 Mar 3. Mol Cancer Ther. 2016. PMID: 26939703 Free PMC article.

7

ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.

Wang R, Lin W, Lin C, Li L, Sun Y, Chang C. Wang R, et al. Among authors: sun y. Cancer Lett. 2016 Aug 28;379(1):154-60. doi: 10.1016/j.canlet.2016.05.018. Epub 2016 May 24. Cancer Lett. 2016. PMID: 27233475

8

Sorafenib with ASC-J9^® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.

Xu J, Lin H, Li G, Sun Y, Shi L, Ma WL, Chen J, Cai X, Chang C. Xu J, et al. Among authors: sun y. Int J Cancer. 2017 Feb 1;140(3):705-717. doi: 10.1002/ijc.30446. Epub 2016 Nov 9. Int J Cancer. 2017. PMID: 27668844 Free PMC article.

9

The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.

Xu J, Lin H, Li G, Sun Y, Chen J, Shi L, Cai X, Chang C. Xu J, et al. Among authors: sun y. EBioMedicine. 2016 Oct;12:55-67. doi: 10.1016/j.ebiom.2016.07.013. Epub 2016 Jul 14. EBioMedicine. 2016. PMID: 27688096 Free PMC article.

10

Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals.

Wang K, Sun Y, Tao W, Fei X, Chang C. Wang K, et al. Among authors: sun y. Cancer Lett. 2017 May 28;394:1-12. doi: 10.1016/j.canlet.2016.12.036. Epub 2017 Jan 13. Cancer Lett. 2017. PMID: 28089832

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65,579 results

Search Page

Filters